Integer (ITGR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Executive summary
The annual meeting is scheduled for May 20, 2026, with voting on key proposals including director elections, auditor ratification, executive compensation, and a new omnibus incentive plan.
Shareholders can vote online, by phone, mail, or in person, with materials provided primarily via internet access to reduce costs and environmental impact.
2025 saw 8% sales growth to $1.854 billion, $221 million in operating income, and significant investments in acquisitions, capital expenditures, and share repurchases.
Voting matters and shareholder proposals
Election of 11 directors for a one-year term.
Ratification of Deloitte & Touche LLP as independent auditor for 2026.
Advisory vote on executive compensation (say-on-pay).
Approval of the 2026 Omnibus Incentive Plan, replacing the 2021 plan and authorizing 1,000,000 new shares plus rollover shares.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
10 of 11 director nominees are independent; strong focus on board refreshment and diversity of skills.
Board committees (Audit, Compensation, Governance, Technology) are fully independent.
Annual board, committee, and individual director evaluations; robust orientation and continuing education.
No poison pill, no supermajority voting, and stockholders have the right to act by written consent.
Latest events from Integer
- 2025 saw 8% sales and 21% EPS growth; 2026 guidance is stable with strong long-term prospects.ITGR
Q4 20259 Apr 2026 - Director elections, auditor ratification, and executive pay are key votes at the 2026 annual meeting.ITGR
Proxy filing6 Apr 2026 - Temporary product headwinds in 2026 are expected to give way to above-market growth in 2027.ITGR
2026 KeyBanc Capital Markets Healthcare Forum18 Mar 2026 - Above-market growth is expected in 2027, driven by a robust pipeline and new product launches.ITGR
Oppenheimer 36th Annual Healthcare MedTech & Services Conference17 Mar 2026 - 2026 outlook projects flat to modest sales growth, strong pipeline, and continued capital discipline.ITGR
47th Annual Raymond James Institutional Investor Conference6 Mar 2026 - Temporary 2026 headwinds expected to give way to above-market growth in 2027 via new launches.ITGR
Citi Annual Global Healthcare Conference 20253 Feb 2026 - Targeting above-market growth and margin expansion through innovation, integration, and M&A.ITGR
2024 Truist Securities MedTech Conference3 Feb 2026 - Q2 sales up 9%, profit outlook raised, and Medical segment growth drove margin gains.ITGR
Q2 20242 Feb 2026 - Raised 2024 guidance, accelerating growth in high-value medtech markets, and strong margin expansion.ITGR
2024 Wells Fargo Healthcare Conference22 Jan 2026